2022-2029 年全球生物成像技術市場
市場調查報告書
商品編碼
1169017

2022-2029 年全球生物成像技術市場

Global Bio-Imaging Technologies Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內(2022-2029 年),生物成像技術的全球市場規模預計將以 4.6% 的複合年增長率增長。

生物成像技術是一種能夠對生物過程進行非侵入性可視化的技術。 幾種技術可用於成像目的。 這些技術對生物過程的侵入性極小,並在沒有物理干擾的情況下提供有關樣品 3D 結構的數據。

市場動態

推動全球生物成像技術市場的主要因素是慢性病的日益流行、研發和臨床試驗的興起以及技術進步。 新產品發布的增加有助於生物成像技術市場的增長。

研發投資的增加和進步、新產品發布的增加預計將推動市場的增長。

這些生物影像技術產品在神經退行性疾□□病、癌症等多種慢性疾病的診斷、預防和治療中的應用以及新產品的不斷推出,正在推動生物影像技術市場的發展。 此外,癌症發病率的增加也推動了市場增長。 許多醫療保健公司正在加緊研發活動以開發新產品。

生物成像技術用於各種疾病的診斷、預防和治療目的。 由於案例數量不斷增加,這些技術的應用市場正在全球範圍內擴大。 此外,預計主要參與者提供的技術先進的產品也將在市場增長中發揮重要作用。

各種新產品的發布、監管批准和研究正在為市場的增長做出貢獻。 例如,2022 年 8 月 3 日,雅培宣布其新型光學相干斷層掃描成像平台(OCT)“Ultreon Software powered”已獲得美國食品藥品監督管理局的批准。 結合人工智能 (AI) 和 OCT,這款創新的成像軟件提供了冠狀動脈血流和閉塞的先進而全面的顯示,協助醫生進行決策,並提供最佳治療路徑。

與生物成像技術相關的高成本預計會阻礙市場增長。

然而,這些生物成像技術的高成本是製約市場增長的主要因素。 其他限制包括可能導致長期遺傳損傷的高劑量輻射。

一般來說,輻射劑量是根據所需的目標輻射來調整的,但它仍然可以誘發癌症。 添加探針或染料會干擾脂質囊泡的特性,並導致實驗偽影,從而導致數據解釋不准確。

COVID-19 影響分析

疫情對全球金融預期、運營和危機應對策略產生了積極影響。 COVID-19 的爆發嚴重影響了醫療保健行業。 由於 COVID,生物成像技術市場取得了巨大收益。 各種研究和診斷中心已經啟動,COVID 及其診斷病例的增加增加了對這些技術的需求。 多項舉措、產品發布、創新、合作和合併正在全球範圍內進行,推動了市場的增長。 例如,2022年6月14日,邁瑞在Euroanaesthesia 2022上宣布推出其全新的TEX20系列超聲系統。 該系統通過提供高圖像清晰度、以患者為中心的信息解決方案、智能工具和經過深思熟慮的設計的面向臨床的工作流程,對其前身進行了改進。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 增加臨床試驗的數量
      • 不斷進步的技術進步
    • 約束因素
      • 生物成像成本高
    • 商機
    • 影響分析

第5章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按技術類型

  • 納米生物成像
  • 光學成像
  • 正電子 CT(正電子發射斷層掃描)
  • 磁共振成像
  • 超聲成像
  • 計算機斷層掃描
  • 輻射診斷成像
  • 熒光生物成像
  • 其他

第8章應用

  • 醫學生物成像
  • 分子生物成像

第 9 章最終用戶

  • 醫院
  • 診斷中心
  • 其他

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第12章公司簡介

  • 通用電氣醫療
    • 公司概況
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Abbott Laboratories
  • Hitachi Medical Corporation
  • Bayer AG
  • Esaote S.p.A
  • Clario
  • Digirad Corporation
  • Bracco
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Hologic Inc.
  • FONAR Corporation

第13章 全球生物成像技術市場-DataM

簡介目錄
Product Code: DMMI1228

Market Overview

The global bio-imaging technologies market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 4.6% during the forecast period (2022-2029).

Bio-imaging technologies are the methods that provide non-invasive visualization of biological processes. Several technologies can be used for imaging purposes. These technologies interfere with the life processes as minimally as possible and provide data on the 3D structure of the sample without any physical interference.

Market Dynamics

The major factors driving the global bio-imaging technologies market are increased chronic disorders, rising research and development and clinical trials, and technological advancements. An increase in novel product launches contributes to the growth of the bio-imaging technologies market.

The increasing investment and advancements in R&D and rising novel product launches are expected to drive the market's growth.

The rising adoption of these bio-imaging technologies products for the diagnosis, prevention, or treatment of various chronic disorders, such as neurodegenerative disorders and cancer, and the rising number of novel product launches drive the bio-imaging technologies market. An increase in the incidence of carcinomas is also aiding market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.

Bio-imaging technologies are used in various diseases for diagnostic, preventive, or treatment purposes. The market for the applications of these technologies is increasing worldwide due to the increasing number of cases. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, regulatory approvals, and research studies contribute to the market's growth. For instance, in August 3, 2022, Abbott announced that its novel optical coherence tomography imaging platform (OCT), Ultreon Software powered, had received clearance from the U.S. Food and Drugs Administration. This is an innovative imaging software that combines artificial intelligence (AI) with OCT to provide high and comprehensive coronary blood flow, and blockages view to physicians to assist their decision-making and offer the best pathway of treatment.

The high cost associated with bio-imaging technologies is expected to hamper the market's growth.

However, the high cost of these bio-imaging technologies is the leading factor restraining the market's growth. Other limitations include high radiation dose delivery that can lead to genetic disorders in the long term.

The radiation dose is generally adjusted at the desired target radiation but can still induce cancer. The probes and dye addition interferes with lipid vesicle properties and can cause experimental artifacts that result in an inaccurate interpretation of data.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations, and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The bio-imaging technologies market has experienced huge profits due to COVID, as various research and diagnostic centers started and demand for these technologies rose due to the increasing cases of COVID and its diagnosis. Multiple initiatives, product launches, innovations, collaborations, and mergers are happening worldwide, boosting the market's growth. For instance, in June 14, 2022, Mindray announced the launch of its novel TEX20 Series ultrasound system at the Euroanaesthesia 2022. This system has improved features than its predecessors as it provides high image clarity, patient-centered information solution, intelligent tools, and clinical-oriented workflow with thoughtful design.

Segment Analysis

The nano bio-imaging segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The nano bio-imaging segment is the highest market holder in the global bio-imaging technologies market. The global bio-imaging technologies market is segmented based on technology type: nano bio-imaging, optical imaging, Positron Emission Tomography, magnetic resonance imaging, ultrasound imaging, computed tomography, radiological imaging, and others. The nano bio-imaging segment is the largest market shareholder due to its better efficacy and results, advantages over other technologies, and rising advancements and adoption of these bio-imaging technologies.

Nanotechnology can solve the high-resolution image construction barrier. Nanotechnology can take Positron Emission Tomography advancements to the next level as it can maximize the resolution in currently available techniques. Nano bio-imaging can increase the target imaging specificity with the help of uniquely designed nano constructs. In medical and Fluorescence Bioimaging research, the enhanced role of nanomaterials reflects nanotechnology's impact in bioimaging. The nano bio-imaging technique or combination of imaging and nanoparticle, most importantly, provides improved contrast images. Various biocompatible nanocrystals and small molecule contrast agents can offer strong imaging signals.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in September 12, 2022, Clario explored neuroimaging or neuromelanin MRI and Opal sensor tech can be beneficial as it improves the precision and quality of the clinical outcome measures hence, characterizing the digital endpoints for decentralized clinical trials at the International Congress of Parkinson's Disease and Movement Disorders 2022.

Geographical Analysis

North America holds the largest market share in the global bio-imaging technologies market.

North America dominates the global bio-imaging technologies market, primarily due to its large population, excellent medical infrastructure, and rising number of chronic disorders. According to the American Cancer Society, in 2022, Around 60.650 estimated novel leukemia cases will occur, out of which 24,000 deaths will appear in the United States. About 1 out of 9 people 65 years or older have dementia; by 2050, this is expected to reach around 12.7 million. The increasing number of brain health issues, cardiovascular disorders, and cancer cases boost the demand for bio-imaging technologies.

Increasing expenditure on healthcare and raising awareness among people are also contributing to the market's growth in this region. Advancement of applications of bio-imaging technologies in the diagnosis and examination of several diseases, providing the database of the physiology of the human body for further studies, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the Bio-Imaging Technologies market.

Moreover, the growing number of product launches is responsible for the market's growth. Many vital developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in May 28, 2021, Mindray, medical devices and solutions developer and provider, launched its novel general imaging, cardiology, and women's healthcare ultrasound solutions. This is developed to increase the diagnostic evidence strength for ensuring improved patient care.

Competitive Landscape

The bio-imaging technologies market is highly competitive with local and global companies' presence. GE Healthcare, Abbott Laboratories, Hitachi Medical Corporation, Bayer AG, Esaote S.p.A, Clario, Digirad Corporation, Bracco, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Hologic Inc., FONAR Corporation, and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in March 31, 2021, FONAR Corporation, an MR Scanning investor, announced its acquisition of a Yonkers, New York-based Stand-Up MRI facility from where Health Management Company of America, FONAR's diagnostic imaging management subsidiary will offer non-medical management services for MRI of New York.

GE Healthcare.

Overview: GE HealthCare is a subsidiary of General Electric, an American multinational conglomerate integrated into New York, founded in 1994 and headquartered in Chicago, Illinois. It manufactures and distributes various diagnostic imaging agents and radiopharmaceuticals that can be used for imaging modalities in some procedures, such as medical imaging.

Product Portfolio:

SIGNA MR: Signa is the MR product that increases the capabilities of magnetic resonance imaging with efficient productivity and workflow solutions for scanning and offers innovations to advanced clinical procedures.

Key Developments: In Oct 2022, GE Healthcare introduced Omni Legend at the annual European Nuclear Medicine Associations meeting. This system is first on its all-novel and digital PET/CT platform as it features the latest, crystal-size digital BGO detector material category capable of providing two times more sensitivity than prior digital scanners.

The global bio-imaging technologies market report would provide access to approx.: 45+ market data tables, 40+ figures, and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing number of clinical trials
      • 4.1.1.2. Rising technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of bio-imaging
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Technology Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 7.1.2. Market Attractiveness Index, By Technology Type
  • 7.2. Nano-Bio Imaging *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Optical Imaging
  • 7.4. Positron Emission Tomography
  • 7.5. Magnetic Resonance Imaging
  • 7.6. Ultrasound Imaging
  • 7.7. Computed Tomography
  • 7.8. Radiological Imaging
  • 7.9. Fluorescence Bioimaging
  • 7.10. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Medical Bio-Imaging *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Molecular Bio-Imaging

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Diagnostic Centers
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. GE Healthcare *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Abbott Laboratories
  • 12.3. Hitachi Medical Corporation
  • 12.4. Bayer AG
  • 12.5. Esaote S.p.A
  • 12.6. Clario
  • 12.7. Digirad Corporation
  • 12.8. Bracco
  • 12.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 12.10. Hologic Inc.
  • 12.11. FONAR Corporation

LIST NOT EXHAUSTIVE

13. Global Bio-Imaging Technologies Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and End-User
  • 13.3. Contact Us